A detailed history of Principal Financial Group Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 11,593 shares of IBRX stock, worth $39,995. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,593
Holding current value
$39,995
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 31, 2025

BUY
$2.56 - $6.17 $29,678 - $71,528
11,593 New
11,593 $29,000
Q3 2024

Oct 31, 2024

SELL
$3.32 - $6.7 $95,303 - $192,330
-28,706 Reduced 69.64%
12,513 $46,000
Q2 2024

Jul 29, 2024

SELL
$4.82 - $9.15 $155,430 - $295,060
-32,247 Reduced 43.89%
41,219 $260,000
Q1 2024

Apr 29, 2024

SELL
$3.23 - $6.17 $9,102 - $17,387
-2,818 Reduced 3.69%
73,466 $394,000
Q4 2023

Feb 07, 2024

BUY
$1.25 - $5.21 $80 - $333
64 Added 0.08%
76,284 $382,000
Q3 2023

Nov 02, 2023

BUY
$1.29 - $3.1 $2,794 - $6,714
2,166 Added 2.92%
76,220 $128,000
Q2 2023

Aug 07, 2023

BUY
$1.53 - $6.41 $14,146 - $59,266
9,246 Added 14.27%
74,054 $205,000
Q1 2023

May 09, 2023

SELL
$1.35 - $4.78 $5,621 - $19,903
-4,164 Reduced 6.04%
64,808 $117,000
Q4 2022

Feb 09, 2023

BUY
$4.35 - $6.77 $51,334 - $79,892
11,801 Added 20.64%
68,972 $349,000
Q3 2022

Nov 09, 2022

BUY
$3.65 - $6.43 $6,124 - $10,789
1,678 Added 3.02%
57,171 $285,000
Q2 2022

Aug 10, 2022

BUY
$2.68 - $6.14 $26,599 - $60,939
9,925 Added 21.78%
55,493 $206,000
Q1 2022

May 09, 2022

SELL
$5.05 - $7.53 $6,302 - $9,397
-1,248 Reduced 2.67%
45,568 $256,000
Q4 2021

Feb 09, 2022

BUY
$5.67 - $10.18 $142,674 - $256,159
25,163 Added 116.21%
46,816 $285,000
Q3 2021

Nov 09, 2021

SELL
$9.17 - $14.24 $32,186 - $49,982
-3,510 Reduced 13.95%
21,653 $211,000
Q2 2021

Aug 10, 2021

BUY
$13.41 - $22.4 $15,729 - $26,275
1,173 Added 4.89%
25,163 $359,000
Q1 2021

May 24, 2021

BUY
$12.83 - $42.25 $307,791 - $1.01 Million
23,990 New
23,990 $570,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.38B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.